JPWO2021105906A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021105906A5 JPWO2021105906A5 JP2022530701A JP2022530701A JPWO2021105906A5 JP WO2021105906 A5 JPWO2021105906 A5 JP WO2021105906A5 JP 2022530701 A JP2022530701 A JP 2022530701A JP 2022530701 A JP2022530701 A JP 2022530701A JP WO2021105906 A5 JPWO2021105906 A5 JP WO2021105906A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- heterocyclyl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims description 428
- 125000000623 heterocyclic group Chemical group 0.000 claims description 425
- 125000001072 heteroaryl group Chemical group 0.000 claims description 423
- 125000000217 alkyl group Chemical group 0.000 claims description 357
- 125000005843 halogen group Chemical group 0.000 claims description 207
- 229910052736 halogen Inorganic materials 0.000 claims description 165
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 151
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 137
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 132
- 125000001424 substituent group Chemical group 0.000 claims description 127
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 121
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 117
- -1 substituted Chemical class 0.000 claims description 112
- 150000002367 halogens Chemical class 0.000 claims description 101
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 82
- 239000012453 solvate Substances 0.000 claims description 82
- 125000003545 alkoxy group Chemical group 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 37
- 229910017711 NHRa Inorganic materials 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 14
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 13
- 208000028226 Krabbe disease Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 10
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 9
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000032859 Synucleinopathies Diseases 0.000 claims description 7
- 208000016192 Demyelinating disease Diseases 0.000 claims description 5
- 102100028496 Galactocerebrosidase Human genes 0.000 claims description 5
- 108010042681 Galactosylceramidase Proteins 0.000 claims description 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims description 5
- 206010058491 Pulmonary artery dilatation Diseases 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- HHJTWTPUPVQKNA-PIIMIWFASA-N psychosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HHJTWTPUPVQKNA-PIIMIWFASA-N 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 description 93
- 230000002265 prevention Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19383036 | 2019-11-25 | ||
| EP19383036.1 | 2019-11-25 | ||
| PCT/IB2020/061156 WO2021105906A1 (fr) | 2019-11-25 | 2020-11-25 | Composés aryle et hétéroaryle, leurs utilisations thérapeutiques dans des conditions associées à l'altération de l'activité de la galactocérébrosidase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503470A JP2023503470A (ja) | 2023-01-30 |
| JPWO2021105906A5 true JPWO2021105906A5 (fr) | 2023-11-24 |
Family
ID=68808238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530701A Pending JP2023503470A (ja) | 2019-11-25 | 2020-11-25 | ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230058312A1 (fr) |
| EP (1) | EP4065546A1 (fr) |
| JP (1) | JP2023503470A (fr) |
| KR (1) | KR20220150880A (fr) |
| CN (1) | CN115397806A (fr) |
| AU (1) | AU2020393174A1 (fr) |
| BR (1) | BR112022010127A2 (fr) |
| CA (1) | CA3158290A1 (fr) |
| IL (1) | IL293409A (fr) |
| MX (1) | MX2022006059A (fr) |
| WO (1) | WO2021105906A1 (fr) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500714A (en) * | 1981-10-15 | 1985-02-19 | Chugai Seiyaku Kabushiki Kaisha | 3-Substituted-ureido-N-pyridyl benzamides |
| US7511066B2 (en) * | 2003-09-30 | 2009-03-31 | Eli Lilly And Company | Antithrombotic aromatic ethers |
| US7470787B2 (en) * | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| JP2011526925A (ja) * | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| EP2411529A4 (fr) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | Modulateurs de la biosynthèse des glycanes n-liés |
| ES2555533T3 (es) | 2009-10-19 | 2016-01-04 | Amicus Therapeutics, Inc. | Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal |
| RU2645675C2 (ru) | 2011-03-18 | 2018-02-27 | Джензим Корпорейшн | Ингибиторы глюкозилцерамид-синтазы |
| WO2013078413A1 (fr) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulateurs du stockage lipidique |
| CN106604913A (zh) * | 2014-03-31 | 2017-04-26 | 纽约哥伦比亚大学理事会 | 组蛋白乙酰基转移酶激活剂及其用途 |
| CA3007462C (fr) * | 2015-12-07 | 2023-10-24 | Plexxikon Inc. | Composes et procedes pour la modulation de kinase, et indications associees |
| AU2017232610B2 (en) * | 2016-03-16 | 2021-07-22 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| KR20190030693A (ko) * | 2016-07-20 | 2019-03-22 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 히스톤 아세틸트랜스퍼라제 활성화제 및 이의 조성물 및 용도 |
-
2020
- 2020-11-25 BR BR112022010127A patent/BR112022010127A2/pt not_active Application Discontinuation
- 2020-11-25 US US17/779,485 patent/US20230058312A1/en active Pending
- 2020-11-25 IL IL293409A patent/IL293409A/en unknown
- 2020-11-25 EP EP20815951.7A patent/EP4065546A1/fr active Pending
- 2020-11-25 AU AU2020393174A patent/AU2020393174A1/en active Pending
- 2020-11-25 JP JP2022530701A patent/JP2023503470A/ja active Pending
- 2020-11-25 CA CA3158290A patent/CA3158290A1/fr active Pending
- 2020-11-25 WO PCT/IB2020/061156 patent/WO2021105906A1/fr active Application Filing
- 2020-11-25 KR KR1020227021341A patent/KR20220150880A/ko unknown
- 2020-11-25 CN CN202080088133.2A patent/CN115397806A/zh active Pending
- 2020-11-25 MX MX2022006059A patent/MX2022006059A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504711A5 (fr) | ||
| RU2201921C2 (ru) | Производные замещенного фенила и фармацевтическая композиция на их основе | |
| JP2020519606A5 (fr) | ||
| WO2006125180B1 (fr) | Derives de piperazine: utilisation comme agents therapeutiques | |
| CA2405796A1 (fr) | Procedes et compositions de modulation de l'activite des recepteurs adrenergiques alpha | |
| IL262177A (en) | Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders | |
| JP2008509187A5 (fr) | ||
| JP2005519908A5 (fr) | ||
| JP2017519836A5 (fr) | ||
| JP5878015B2 (ja) | スフィンゴシン一リン酸受容体調節因子および筋肉炎症を治療するためのその使用 | |
| CA2628848A1 (fr) | Compositions et procedes de traitement de la thrombocytopenie | |
| JP2020504122A5 (fr) | ||
| JP2005532397A5 (fr) | ||
| MX2007012070A (es) | Tratamiento de la epilepsia con ligandos del receptor h3 de histamina, tipo alquilaminas no imidazol. | |
| EP0285219B1 (fr) | Méthode pour améliorer le sommeil | |
| JP2005513017A5 (fr) | ||
| JP2003501469A5 (fr) | ||
| RU98119076A (ru) | Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2 | |
| JP2018525447A5 (fr) | ||
| MXPA04006777A (es) | Ligandos de receptor de histamina-3 para condiciones diabeticas. | |
| JPWO2021105906A5 (fr) | ||
| JP2012006918A (ja) | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤 | |
| US7674792B2 (en) | 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one | |
| AU2004275852A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| RU2015114405A (ru) | Замещенные соединения фенилкарбамата |